Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.
Novo Nordisk blew out the first quarter, with sales increases all over the place, and a 73% leap in earnings. But the most surprising part of that press release is slotted in at the very end: "Kåre Schultz, president and COO, leaves Novo Nordisk. Read more >>
With Mylan's second bid for Perrigo, it actually hit below the first bid the Irish drugmaker rejected, Perrigo contended. But now, Mylan is back with a third offer to set things straight. Read more >>
After expecting to eventually take the CEO seat at Novo Nordisk, Kåre Schultz is out of a job this week amid an executive reshuffle at the company. Read more >>
POPULAR COMMENT THREADS
An Express Scripts unit agreed to settle claims with the U.S. Department of Justice that it participated in a scheme with Novartis that ended in improper government reimbursements. And if the DOJ has its way, the settlement could lead to more legal action against Novartis in a separate suit.
GlaxoSmithKline CEO Andrew Witty recently said slow-starting respiratory newcomer Breo was finally gaining some market traction. And now, it has a new asthma indication the company hopes can help speed things along.
Since before Teva even made its now-rejected $40 billion offer to buy Mylan, its target's exec chairman, Robert Coury, has been pretty down on the idea, citing a potential culture clash between the two companies. While Teva CEO Erez Vigodman has said he thinks they'd get along just fine, the rival drugmakers do have a few big differences between them--including their approach to executive compensation.
It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.
Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.
No one can pin down Pfizer CEO Ian Read when it comes to whether the company will split up--not publicly, anyway. That word won't come till late next year at least. But repeated questioning from analysts during the company's first-quarter earnings call did yield some facts in the matter.
From Our Sister Sites
The head of the FDA's device arm (CDRH) acknowledged that the division is failing to live up to its vision that "patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world" because advanced devices like transaortic valve replacements are regularly approved in Europe 5 years earlier than the U.S, but cited statistics showing that CRDH has been getting devices to market faster in an April 30 address.
Reuters takes a look at the technology revolution that's expected to enable the next step beyond wearables: devices that are so tiny and integrated with the human body that they are barely noticeable to the wearer or others.